HEFT Repository

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

Nightingale, Sam and Chau, Tran Thi Hong and Fisher, Martin and Nelson, Mark and Winston, Alan and Else, Laura and Carr, Daniel F and Taylor, Steven and Ustianowski, Andrew and Back, David and Pirmohamed, Munir and Solomon, Tom and Farrar, Jeremy and Törok, M Estée and Khoo, Saye H (2016) Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial agents and chemotherapy, 60 (8). pp. 4511-8. ISSN 1098-6596.

[img]
Preview
Text (PDF file format)
Efavirenz and Metabolites in Cerebrospinal Fluid Relationship with CYP2B6 c516G T Genotypr and Perturbed Blood Bain Barrier Due to Tuberculous Meningitis.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (889kB) | Preview
Official URL: http://aac.asm.org/content/60/8/4511.long

Abstract

Efavirenz (EFZ) has been associated with neuropsychiatric side effects. Recently, the 8-hydroxy-EFZ (8OH-EFZ) metabolite has been shown to be a potent neurotoxin in vitro, inducing neuronal damage at concentrations of 3.3 ng/ml. EFZ induced similar neuronal damage at concentrations of 31.6 ng/ml. We investigated the effect of genotype and blood-brain barrier integrity on EFZ metabolite concentrations in cerebrospinal fluid (CSF). We measured CSF drug concentrations in subjects from two separate study populations: 47 subjects with tuberculous meningitis (TBM) coinfection in Vietnam receiving 800 mg EFZ with standard antituberculous treatment and 25 subjects from the PARTITION study in the United Kingdom without central nervous system infection receiving 600 mg EFZ. EFZ and metabolite concentrations in CSF and plasma were measured and compared with estimates of effectiveness and neurotoxicity from available published in vitro and in vivo data. The effect of the CYP2B6 c.516G→T genotype (GG genotype, fast EFV metabolizer status; GT genotype, intermediate EFV metabolizer status; TT genotype, slow EFV metabolizer status) was examined. The mean CSF concentrations of EFZ and 8OH-EFZ in the TBM group were 60.3 and 39.3 ng/ml, respectively, and those in the no-TBM group were 15.0 and 5.9 ng/ml, respectively. Plasma EFZ and 8OH-EFZ concentrations were similar between the two groups. CSF EFZ concentrations were above the in vitro toxic concentration in 76% of samples (GG genotype, 61%; GT genotype, 90%; TT genotype, 100%) in the TBM group and 13% of samples (GG genotype, 0%; GT genotype, 18%; TT genotype, 50%) in the no-TBM group. CSF 8OH-EFZ concentrations were above the in vitro toxic concentration in 98% of the TBM group and 87% of the no-TBM group; levels were independent of genotype but correlated with the CSF/plasma albumin ratio. Potentially neurotoxic concentrations of 8OH-EFZ are frequently observed in CSF independently of the CYP2B6 genotype, particularly in those with impaired blood-brain barrier integrity.

Item Type: Article
Subjects: QV Pharmacology
Divisions: Clinical Support > Infectious Diseases
Related URLs:
Depositing User: Miss Adele Creak
Date Deposited: 27 Feb 2017 13:33
Last Modified: 27 Feb 2017 13:33
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1211

Actions (login required)

View Item View Item